

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Observed concentrations of amikacin and gentamycin in the setting of burn patients with gram-negative bacterial infections: Preliminary data from a prospective study

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1785591> since 2021-10-21T13:43:35Z

Published version:

DOI:10.1016/j.therap.2020.10.003

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

Therapies

Observed concentrations of Amikacin and Gentamycin in the Setting of Burn Patients with Gram-Negative Bacterial infections: preliminary data from a prospective study --Projet de manuscrit--

Numéro du manuscrit:	THERAP-D-20-00101R3
Type d'article:	Article original / Original Article
Second titre complet:	
Mots-clés:	Pharmacokinetic; burn; Amikacin; Gentamicin; Gram-negative; infections
Mots-clés secondaires:	
Auteur correspondant:	Tommaso Lupia Universita degli Studi di Torino Scuola di Medicina ITALY
Premier auteur:	Silvia Corcione
Ordre des auteurs:	Silvia Corcione Amedeo De Nicolò Tommaso Lupia Francesco V Segala Anna Pensa Riccardo Corgiat Loia Maria R Romeo Maurizio Stella Giovanni Di Perri Antonio D'Avolio Francesco G De Rosa
Résumé:	<p>Aim of the Study Critically ill populations often have shown subtherapeutic aminoglycosides' concentrations mostly because of unavoidable changes in drug volume distribution and clearance. We present a real life prospective study evaluating plasma concentrations for once-daily dosing for amikacin and gentamycin among a population of severe burn adults.</p> <p>Methods We conducted a real life prospective study on the plasma concentrations of amikacin and gentamycin among severe burn patients, using aminoglycoside as combination therapy. Antibiotics were prescribed at the standard doses of 15-20 mg/kg/day for amikacin and 3-5mg/kg/day for gentamycin</p> <p>Results Eight patients (4 in amikacin and 4 in gentamycin groups, respectively) were enrolled in the study. All subjects were admitted for severe burns. The most common site of infection was bloodstream (5; 62.5%) and pneumonia (4; 50%). <i>Pseudomonas aeruginosa</i>, followed by <i>Klebsiella pneumoniae</i> and multi-drug resistant <i>Acinetobacter baumannii</i> were the most prevalent agents isolated. Amikacin and gentamycin never achieved the target peak concentration of 60mg/L and 30mg/L: in our study C_{max}, for amikacin, was 33.1 ± 15.6mg/L (SD), while for gentamycin was 14.3 mg/L ± 9. C_{max} and total body surface area have shown a strong negative correlation with borderline statistical significance (amikacin: $p=0.922$, $p=0.078$; gentamycin: $p=0.937$, $p=0.063$). At the standard dosage, the pharmacokinetic/pharmacodynamic (PK/PD) target of $C_{max} > 8 \times$ highest MIC was reached for 8 (53.3%) out of 15 isolated pathogens.</p> <p>Conclusions The present study found that, in a population of septic burn patients, standard doses of</p>

	gentamycin and amikacin most often lead to plasma concentrations under the PK/PD target
Résumé secondaire:	
Évaluateurs suggérés:	Nicola Petrosillo nicola.petrosillo@inmi.it



UNIVERSITÀ DEGLI STUDI DI TORINO
DIPARTIMENTO DI SCIENZE MEDICHE

Turin, September 19th 2020

Dear Editor,

Thanks for the opportunity to revise our manuscript. Please find the response to reviewers' comments on our manuscript entitled "**Observed concentrations of Amikacin and Gentamycin in the Setting of Burn Patients with Gram-Negative Bacterial infections: preliminary data from a prospective study**" to be considered for publication in *Therapies*

Reviewer comments

Thanks you for your revision which improve the manuscript. Few issues are still remaining.

1) Discussion section: Please modify the following sentence in order to improve understanding : "Thirdly, we use exact MIC value and clinical breakpoints in the pharmacological analysis, despite that using ECOFF as MIC value is more appropriate in ICU than the use of clinical breakpoints for defining PK-PD targets of an antibiotic treatment" to "Thirdly, in the PK-PD analysis we use clinical breakpoints when exact MIC value were not available, despite that using ECOFF as MIC value is more appropriate in ICU population (Guilhaumou et al., Critical Care, 2019)."

Thank you for these corrections. The sentence was modified in the text.

2) Conclusion: Line 20-21 page 5 : Please correct « concetrations ».

Thank you for these correction. The word was corrected in the text.

3) Ethics approval: Please correct the discrepancy between "Ethics approval and consent to participate section" ("Informed consent was waived due to the retrospective nature of the study. The study was performed by ICH-GCP guidelines and the declaration of Helsinki")



UNIVERSITÀ DEGLI STUDI DI TORINO
DIPARTIMENTO DI SCIENZE MEDICHE

and "Methods" section ("The study was approved by the local ethical committee (PROT. N.0063741) and written informed consent was obtained from all patients before the sampling").

Thank you for this suggestion that improve the manuscript. Right formi s the second one, presented in method section. We have modify also ethics approval.

Sincerely,

Tommaso Lupia, MD
Department of Medical Sciences, Infectious Diseases
University of Turin, Italy
email: tommaso.lupia89@gmail.com

THERAPIES

HEADING: Pharmacokinetics

Observed concentrations of amikacin and gentamycin in the setting of burn patients with gram-negative bacterial infections: preliminary data from a prospective study

Pharmacokinetics of amikacin and gentamycin

Silvia Corcione^{a,b}, Amedeo De Nicolò^c, Tommaso Lupia^{a,*}, Francesco Vladimiro Segala^a, Anna Pensa^d, Riccardo Corgiat Loia^a, Maria Rosa Romeo^d, Giovanni Di Perri^a, Maurizio Stella^d, Antonio D'Avolio^c, Francesco Giuseppe De Rosa^a

^a *Department of Medical Sciences, Infectious Diseases, University of Turin, 10124 Turin, Italy*

^b *Tufts University School of Medicine, 02111 Boston, MA, USA*

^c *Department of Medical Sciences; University of Turin - ASL 'Città di Torino' Laboratory of Clinical Pharmacology and Pharmacogenetics; Amedeo di Savoia Hospital, 10149 Turin, Italy*

^d *Burn Centre, C.T.O Hospital, A.O.U. Città della Salute e della Scienza, 10126 Turin, Italy*

Text received May 26, 2020; accepted September 17, 2020

***Corresponding author.** Department of Medical Sciences, Infectious Diseases, University of Turin, Turin, Via Verdi 8, 10124, Italy.

Email adress: tommaso.lupia89@gmail.com (T. Luppia)

Summary

1
2
3
4
5 *Aim of the study.*- Critically ill populations often have shown subtherapeutic aminoglycosides'
6 concentrations mostly because of unavoidable changes in drug volume distribution and clearance.
7
8 We present a real life prospective study evaluating plasma concentrations for once-daily dosing for
9 amikacin and gentamycin among a population of severe burn adults. *Methods.*- We conducted a real
10 life prospective study on the plasma observed concentrations of amikacin and gentamycin among
11 severe burn patients, using aminoglycoside as combination therapy. Antibiotics were prescribed at
12 the standard doses of 15-20 mg/kg/day for amikacin and 3-5mg/kg/day for gentamycin. *Results.*-
13 Eight patients (4 in amikacin and 4 in gentamycin groups, respectively) were enrolled in the study.
14 All subjects were admitted for severe burns. The most common site of infection was bloodstream
15 (5; 62.5%) and pneumonia (4; 50%). *Pseudomonas aeruginosa*, followed by *Klebsiella pneumoniae*
16 and multi-drug resistant *Acinetobacter baumannii* were the most prevalent agents isolated.
17 Amikacin and gentamycin never achieved the target peak concentration of 60mg/L and 30mg/L: in
18 our study C_{max} , for amikacin, was 33.1 ± 15.6 mg/L (SD), while for gentamycin was 14.3 mg/L ± 9 .
19 C_{max} and total body surface area have shown a strong negative correlation with borderline
20 statistical significance (amikacin: $\rho = 0.922$, $p = 0.078$; gentamycin: $\rho = 0.937$, $p = 0.063$). At the
21 standard dosage, the pharmacokinetic/pharmacodynamic (PK/PD) target of $C_{max} > 8 \times$ highest MIC
22 was reached for 8 (53.3%) out of 15 isolated pathogens. *Conclusions.*- The present study found that,
23 in a population of septic burn patients, standard doses of gentamycin and amikacin most often lead
24 to plasma concentrations under the PK/PD target
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

KEYWORDS

43
44
45 Pharmacokinetic; Burn; Amikacin; Gentamicin; Gram-negative; Infections
46
47
48
49

Abbreviations

50
51
52 AGs: aminoglycosides
53

54
55 AMK: amikacin
56

57
58 C_{max} : peak drug concentration
59

60
61 EUCAST: European Committee on Antimicrobial Susceptibility Testing
62
63
64
65

1 GEM: gentamycin

2 IV: intravenous

3
4 MIC: minimum inhibitory concentration

5
6
7 PD: pharmacodynamic

8
9
10 PK: pharmacokinetic

11
12 TBSA: total body surface area

13
14
15 TDM: therapeutic drug monitoring

16
17 Vd: volume distribution

18 19 20 21 22 **Introduction**

23
24
25
26
27 Aminoglycosides (AGs) have been commonly used as a part of the combination regimen for
28 managing bacterial infections in severe burn patients, increasing the chance of initial effective therapy
29 [1]. Infection is the most frequent complication encountered by burn patients, with a high risk of
30 gram-positive isolates immediately after hospital admission and a risk of gram-negative bacteria that
31 increases with the length of hospital stay [2-3]. AGs display a concentration-dependent killing
32 activity; thus, the rate and extent of bacterial killing are driven by peak drug concentrations (i.e., C_{max})
33 [4]. Pharmacodynamic, bacteriological and toxicological expertise have allowed for increasingly
34 higher usage of aminoglycosides in once-daily dosing regimens, due to its ability to achieve desirable
35 antibiotic blood concentration and potentially reduce the risk of nephrotoxicity [5]. Severe burn
36 patients often show subtherapeutic AG concentrations, mostly due to changes in volume distribution
37 (Vd) and clearance [6]. Hence, the pharmacodynamic (PD) target – the ratio of C_{max} to the minimum
38 inhibitory concentration (MIC) ≥ 8 (notably by eight-fold to twelve-fold) after the first dose – is often
39 difficult to achieve [6]. A weight-based dose adjustment scheme, commonly known as the Hartford
40 nomogram, has been recommended for the treatment of gram-negative infections; dosing correction
41 was based on pharmacokinetic (PK) data derived from the general patient population [7]. However,
42 the recommended AG dose is likely to be insufficient to achieve target peak drug concentrations in
43 critically ill patients due to differences in PK compared with the general patient population. PK
44 parameters AG are much more variable in critically ill patients, and in the severe burn patients
45 themselves, than in the general population. Therefore, treatment of critically ill patients requires

1 frequent dose changes and therapeutic drug monitoring (TDM) practice to achieve therapeutic
2 antibiotic concentrations and maximise effectiveness and safety [8-11].
3

4 We aimed to describe observed concentrations of amikacin (AMK) and gentamycin (GEM)
5 in a population of severe burn patients.
6
7
8
9

10 11 12 13 **Methods** 14 15 16 17

18 We conducted a real life prospective study on the plasma concentrations of AMK and GEM among
19 severe burn patients. Antibiotics were prescribed at the standard, in label, doses of 15-20 mg/kg/day
20 for AMK and 3-5 mg/kg/day for GEM. The target peak concentrations (C_{max}) for AMK and GEM
21 were, respectively, 60 mg/L and 30 mg/L, according to the European Committee on Antimicrobial
22 Susceptibility Testing (EUCAST) definitions, and the target pharmacokinetic/pharmacodynamic
23 (PK/PD) ratio was defined as a $C_{max} > 8 \times$ highest MIC [12]. Both drugs were given intravenously
24 (IV) over 30 minutes, either as empirical or targeted therapy. The study was approved by the local
25 ethical committee (PROT. N.0063741) and written informed consent was obtained from all patients
26 before the sampling. All subjects admitted to the Burn Center of Turin, Italy from January 2016 to
27 April 2018 and treated with AMK or GEM, either empirically or as target therapy, were enrolled in
28 the study. Complete demographic characteristics, medical histories and clinical parameters were
29 collected from each subject, including days of hospitalisation, blood chemistries, renal function and
30 specific burn indices. Sepsis and septic shock were classified according to the Third International
31 Consensus Definition (Sepsis-3) [13]. Microbiological data, where available, were also collected.
32
33
34
35
36
37
38
39
40
41
42
43
44

45 Plasma aminoglycosides concentrations were determined at steady-state ≥ 48 h after the
46 beginning of therapy. The first blood sampling was performed immediately before the antibiotic
47 administration (T0) and, another sample was obtained at the end of the infusion (T1). The C_{max} is
48 defined as the concentration at the end of the infusion. Blood samples were collected in lithium
49 heparin tubes (7 mL) and plasma was obtained by centrifugation at 1400 X g for 10 min at 4 °C (ALC
50 PK 130R refrigerated centrifuge; DJB Labcare Ltd., Newport Pagnell, UK). Each sample was stored
51 at - 20 °C until analysis (<3 weeks). Stability tests performed during method validation reported drug
52 stability (<5% degradation) within 1 month (data not shown). AMK and GEM concentrations were
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

determined in the setting of routine clinical care via the HPLC-photodiode method (HPLC-photodiode array).

Descriptive and correlation statistical analysis were performed using SPSS 24.0 software (IBM).

Results

Eight patients were enrolled in the study – four in the AMK treatment group and four in the GEM treatment group. Patients' characteristics are shown in Table 1. All subjects were admitted for severe burns, involving 10–55% of their total body surface area (TBSA), with a mean Revised Baux Score of 104.5 ± 50.4 . Six patients (75%) required mechanical ventilation and two had septic shock [13]. The most common sites of infection were the bloodstream (5; 62.5%) and pneumonia (4; 50%). In three cases (37.5%), infection involved more than one site. The most frequently isolated bacteria were *Pseudomonas aeruginosa*, followed by *Klebsiella pneumoniae* and multidrug-resistant *Acinetobacter baumannii* (Table 2). The administration of 15–20 mg/kg of AMK and 3–5 mg/kg of GEM never achieved the respective target peak concentrations of 60 mg/L and 30 mg/L (Table 2). The mean C_{\max} was 33.1 ± 15.6 mg/L (SD) for AMK and 14.3 mg/L ± 9 (SD) for GEM. C_{\max} values for both AMK and GEM were negatively correlated with burn surface area (e.g., TBSA), with borderline statistical significance (AMK: $\rho = 0.922$, $p = 0.078$; GEM: $\rho = 0.937$, $p = 0.063$). At the standard dosage, the PK/PD target of $C_{\max} > 8 \times$ highest MIC was reached for 8 (53.3%) out of 15 isolated pathogens. No incidents of acute kidney failure were reported during aminoglycosides treatment.

Discussion

Complex haemodynamic changes occurring in critically ill burn patients may be different depending on the phase after the burn injury [8]. In the early phase, there is a greater volume of distribution (Vd) that may be due to weight gain secondary to aggressive IV fluid resuscitation (i.e., Parkland formula), flanked by hypoalbuminemia and a variable glomerular filtration rate [6]. The latter is one of the most

1 predictive markers for AG clearance, along with Vd, and it is linked to the presence of renal
2 dysfunction: decreased urine output may denote low renal blood flow and AG clearance, on the other
3 hand in the absence of organ dysfunction, AG output could result consistently increased [6-7]. Altered
4 pharmacokinetics in burn patients may affect antibiotic plasma concentrations and, in most studies,
5 the C_{max} for aminoglycosides was always below therapeutic plasma level, with high interindividual
6 variability [10]. However, these changes are generally not considered when deciding upon antibiotic
7 doses for these patients, despite Beaucaire et al. showing a worse outcome in critically ill patients
8 when the C_{max} remained at < 40 g/mL [13]. We reported the PK /PD characteristics of a single daily
9 dose of AMK and GEM, at the standard doses of 15-20 mg/kg and 3-5 mg/kg, respectively, in a small
10 population of burn patients with severe infections caused by gram-negative bacteria. We observed
11 that the standard doses of AMK and GEM never achieved the respective target peak concentrations
12 of 60 mg/L and 30 mg/L, with low mean C_{max} values (33.1 mg/L and 14.3 mg/L, respectively). Conil
13 and colleagues [14] showed that administration of higher doses, particularly of AMK, (e.g., 20 mg/kg)
14 was insufficient to ensure the goal of C_{max}/MIC ratio up to six-fold, achieved in only 47% (18/28) of
15 cases. Several studies used TDM with dose modification to achieve concentrations within a
16 predefined range in the general population: AMK at a standard dosage of 14–15 mg/kg has reached
17 target concentration range in 91–100% [15], while GEM at a dosage of 5–7 mg/kg has reached target
18 concentration range in 96–98% [16]. In Jenkins et al. [15] and Plajer et al. [16] studies target
19 concentrations were achieved with satisfactory percentages through higher dosages of
20 aminoglycosides compared to this cohort and with the use of TDM. Our population statistical analysis
21 demonstrated a negative relationship between C_{max} and the area of the burn for AMK and GEM, as
22 previously reported by Conil et al. [14], with a strong correlation but with borderline statistical
23 significance, likely due to the low number of patients. Moreover, in this small sample, PK/PD target
24 for efficacy ($C_{max}/MIC \geq 8$) was reached in 53.3%. of subjects No theoretical drug or drug interactions
25 have been observed with concomitant therapies. Higher doses of AG were investigated in a
26 subsequent study by Roger et al. in a non-burnt critically ill population: only 59% of patients led to
27 target peak serum concentrations after the administration of 30 mg/kg and 8 mg/kg of AMK and
28 GEM, respectively [10]. Low peak AG concentrations were also confirmed in other studies that
29 proposed higher dosages or intensive TDM [5-7]. This study had several limitations. First, the number
30 of patients receiving AMK or GEM was too small for the assessment of the impact of confounding
31 factors, such as co-morbidities or synergism or drug interactions with chronic or concomitant
32 therapies, that might have led to further reductions or modifications in peak concentrations. Secondly,
33 we did not evaluate the impact of those antibiotics on clinical outcomes and renal function. Thirdly,

1
2 in the PK-PD analysis we use clinical breakpoints when exact MIC value were not available, despite
3 that using ECOFF as MIC value is more appropriate in ICU population [17].
4
5
6
7
8

9 **Conclusions**

10
11
12
13
14 We reported preliminary data from a small, single-centre, real life prospective study on PK/PD of
15 aminoglycosides in burn patients. In literature, most of data on PK/PD and observed concentrations
16 of aminoglycosides are retrospective analysis and no prospective trial. In our prospective study we
17 found that in a population of septic burn patients, standard doses of GEM and AMK most often lead
18 to plasma concentrations under the PK/PD target and peak concentrations might be significantly
19 lower in burn patients compared to those described in critically ill patients [5, 14]; therefore, it may
20 be helpful using higher doses of AMK and GEM, using TDM in clinical practice to avoid sub-optimal
21 therapies and to avoid overexposure and toxicity.
22
23
24
25
26
27
28
29
30

31 **Funding**

32
33 None to declare
34

35 **Ethics approval and consent to participate**

36
37 The study was approved by the local ethical committee (PROT. N.0063741) and written informed
38 consent was obtained from all patients before the sampling
39
40

41 **Availability of data and material**

42
43 The datasets used and analyzed during the current study are available from the corresponding author
44 on reasonable request.
45

46 **Disclosure of interest**

47
48 The authors declare that they have no competing interests or conflicts of interest.
49

50 **Authors' contributions**

51
52 SC and FGDR conceived the study, AP, FVG, RCL, TL collected, analyzed and interpreted the data,
53 and elaborated the manuscript. MS, AD, FGDR supervised the study, corrected the final version of
54 the manuscript. All authors read and approved the final version of the manuscript. We state that the
55 results presented in this paper have not been published previously in whole or part, except in abstract
56 format.
57
58
59
60
61
62
63
64
65

References

- [1] Pitiriga V, Dimitroulia E, Saroglou G, Tsakris A (2017) The challenge of curbing aminoglycoside resistance: can antimicrobial stewardship programs play a critical role? *Expert Rev Anti Infect Ther* 2017;15(10):947-54.
- [2] Lachiewicz AM, Hauck CG, Weber DJ, Cairns BA, van Duin D. Bacterial infections after burn injuries: impact of multidrug resistance. *Clin Infect Dis* 2017;65(12):2130–6.
- [3] Corcione S, Pensa A, Castiglione A, Lupia T, Bortolaso B, Romeo MR, et al. Epidemiology, prevalence and risk factors for infections in burn patients: results from a regional burn centre's analysis. *J Chemother* 2020:1-5. doi: 10.1080/1120009X.2020.1780776. <https://www.tandfonline.com/doi/full/10.1080/1120009X.2020.1780776>.
- [4] Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. *J Infect Dis* 1987;155(1):93-9.
- [5] Lee C, Walker SAN, Walker SE, Seto W, Simor A, Jeschke M. A prospective study evaluating tobramycin pharmacokinetics and optimal once daily dosing in burn patients. *Burns* 2017;43(8):1766-74.
- [6] Tängdén T, Ramos Martín V, Felton TW, Nielsen EI, Marchand S, Brüggemann RJ, et al. The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections. *Intensive Care Med* 2017;43(7):1021-32.
- [7] Blanchet B, Jullien V, Vinsonneau C, Tod M. Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients. *Clin Pharmacokinet* 2008;47(10):635–54.
- [8] Hollingsed TC, Harper DJ, Jennings JP, Morris SE, Saffle JR. Aminoglycoside dosing in burn patients using first-dose pharmacokinetics. *J Trauma* 1993;35(3):394–8.
- [9] Hoey LL, Tschida SJ, Rotschafer JC, Guay DR, Vance-Bryan K. Wide variation in single, daily-dose aminoglycoside pharmacokinetics in patients with burn injuries. *J Burn Care Rehabil* 1997;18(2):116–24.
- [10] Roger C, Nucci B, Louart B, Friggeri A, Knani H, Evrard A, et al. Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsis. *J Antimicrob Chemother* 2016;71(1):208–12.

- 1
2 [11] Craig WA, Redington J, Ebert SC. Pharmacodynamics of amikacin in vitro and in mouse thigh
3 and lung infections. *J Antimicrob Chemother* 1991;27(Suppl. C) 29–40
4
5 [12] Rhodes A, Evans L, Alhazzani W, Levy M, Antonelli M, Ferrer R, et al. Surviving sepsis
6 campaign: international guidelines for management of sepsis and septic shock. *Crit Care Med*
7 2017;45(3):486-552.
8
9 [13] Beaucaire G, Leroy O, Beuscart C, Karp P, Chidiac C, Caillaux M. Clinical and
10 bacteriological efficacy, and practical aspects of amikacin given once daily for severe infections. *J*
11 *Antimicrob Chemother* 1991;27 Suppl C:91-103.
12
13 [14] Conil JM, Georges B, Breden A, Segonds C, Lavit M, Seguin T, et al. Increased amikacin
14 dosage requirements in burn patients receiving a once-daily regimen. *Int J Antimicrob Agent*
15 2006;28(3):226-30.
16
17 [15] Jenkins A, Thomson AH, Brown NM, Semple Y, Sluman C, MacGowan A, et al. Amikacin
18 use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either
19 outcome or adverse events? A systematic review. *J Antimicrob Chemother* 2016;71(10):2754-9.
20
21 [16] Plajer SM, Chin PK, Vella-Brincat JW, Buffery PJ, Begg EJ. Gentamicin and renal function:
22 lessons from 15 years' experience of a pharmacokinetic service for extended interval dosing of
23 gentamicin. *Ther Drug Monit.* 2015;37(1):98-103.
24
25 [17] Guilhaumou R, Benaboud S, Bennis Y, Dahyot-Fizelier C, Dailly E, Gandia P, et al.
26 Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the
27 French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et
28 Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société
29 Française d'Anesthésie et Réanimation-SFAR). *Crit Care* 2019;23(1):104.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Table 1. Patient characteristics and plasma concentrations

Table 2. Microbiological features and observed concentrations

Table 1: Patient Characteristics and Plasma Concentrations

Patient Code	Antibiotic	Gender	Age	BMI	TBSA (%)	RBS	Septic Shock	Creatinine clearance (ml/min)	CVVH	Cmin (mg/L)	Cmax (mg/L)
1	GEM	F	78	25	30	125	No	39	Yes	3,2	13,9
2	GEM	F	46	25	25	71	No	170	No	<0,2	23,7
3	GEM	M	43	29.4	55	115	No	100	Yes	2,2	5,7
4	GEM	M	64	27.8	45	127	Yes	95	No	0,5	8,9
5	AMK	M	67	26	30	114	No	106	No	<1,0	33,9
6	AMK	M	25	22	50	92	Yes	87	No	<1,0	23,9
7	AMK	M	81	27.8	40	138	No	279	No	<1,0	19,7
8	AMK	F	26	19.5	10	54	No	187	No	1,4	54,7
Mean ± S.D.			53.8 ± 22	25.3 ± 3.2	35.6 ± 14.7	104.5 ± 29.5		132.9 ± 75.4			GEM: 14.3 ± 9; AMK: 33.1 ± 15.6
Median			55	25.5	114.5	114.5		103			GEM: 13.9; AMK: 28.9

Legend (Table 1): S.D. : standard deviation; GEM: gentamicin; AMK; amikacin; BMI: body mass index; M: male; F: female; TBSA: total burn surface area; RBS: revised BAUX score; CVVH: continuous veno-venous hemofiltration; MIC: minimum inhibitory concentration; C: concentration

Table 2: Microbiological Features and Observed Concentrations

Patient Code	Aminoglicosides (AG)	Pathogens Isolated	Site of infections	MIC (exact)	Breakpoint for AG	Cmax/MIC
1	GEM	MSSA	Wound Swab	1	S ≤1	6,9
		E.cloacae		2	S ≤2	6,9
		P.vulgaris		4	R >2	3,4
2	GEM	E.Coli	Blood Culture	2	S ≤2	11,8
		P.aeruginosa		2	IE	
3	GEM	K.pneumoniae	Blood Culture	2	S ≤2	2,8
4	GEM	S.marcescens	Blood Culture	2	S ≤2	4,4
5	AMK	P.Aeruginosa A.baumannii MDR	Bronchial Aspirate	8	S ≤16	4,2
				16	R > 8	2,1
6	AMK	P.Aeruginosa S.Marcescens M.morganii	Wound Swab	8	S ≤16	2,9
				8	S ≤8	
				8	S ≤8	
7	AMK	A.baumannii MDR	Blood Culture	8	R > 8	2,4
8	AMK	K.pneumoniae	Blood Culture	4	R >2	13,6

Legend (Table 2): GEM: gentamicin; AMK; amikacin; MIC (exact): minimum inhibitory concentration; C: concentration; MSSA: Methicillin-susceptible S.aureus; S: sensible; R: resistant; AG: aminoglycosides